[Economic assessment of Caelyx versus topotecan in advanced ovarian cancer].

@article{Girre2003EconomicAO,
  title={[Economic assessment of Caelyx versus topotecan in advanced ovarian cancer].},
  author={V{\'e}ronique Girre and {\'E}ric Pujade-Lauraine and Isabelle Durand-Zaleski},
  journal={Bulletin du cancer},
  year={2003},
  volume={90 11},
  pages={983-8}
}
UNLABELLED Ovarian cancer is the most frequent cause of death due to gynecologic malignancy in both the United States and in Europe. A phase III investigation compared second line treatment Caelyx with topotecan in patients with advanced epithelial ovarian carcinoma who failed a first-line platinum-containing regimen. A total of 474 patients were enrolled Although no significant advantage of Caelyx over topotecan with regards to overall survival and progression was found, there were fewer… CONTINUE READING